SPARC study site
High Point, North Carolina, 27262, United States
NCT Number: NCT00947661
A single-blind , 12-week, parallel group clinical study is planned to evaluate the efficacy and safety of SPARC0912 and Reference0912. SPARC0912 is an experimental drug having similar active ingredient but containing a different preservative as that in Reference0912. Patients with open angle glaucoma or ocular hypertension will be enrolled and randomly assigned to receive either product. One drop will be instilled to the study eye nightly at 8:00 PM.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
High Point, North Carolina, 27262, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eye drops, once daily, 12 weeks
Eye drops, once daily, 12 weeks
Time frame: 12 weeks
95% CI for the difference between treatment groups in estimated mean change from baseline was computed for each a total of 12 time points (for the reduction in intraocular pressure from baseline to Week 12)
Sun Pharma Advanced Research Company Limited
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07082816
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsNCT06441643
Eye Diseases, Glaucoma
Garden Grove, California, United States
View Trial DetailsNCT04630808
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsNCT03750201
Eye Diseases, Glaucoma
Beersheba, Israel
View Trial Details